©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Intracellular Localization and Metabolism of Chylomicron Remnants in the Livers of Low Density Lipoprotein Receptor-deficient Mice and ApoE-deficient Mice
EVIDENCE FOR SLOW METABOLISM VIA AN ALTERNATIVE apoE-DEPENDENT PATHWAY (*)

(Received for publication, July 24, 1995; and in revised form, September 27, 1995)

Bok-Cheng Mortimer (§) Dianne J. Beveridge Ian J. Martins Trevor G. Redgrave

From the Department of Physiology, University of Western Australia, Nedlands, Australia 6907

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

The metabolism of chylomicron remnants in mice deficient in low density lipoprotein receptor (LDLr) or apolipoprotein E (apoE) was compared with that of control C57BL/6J mice. Mice were injected intravenously with chylomicron-like emulsions labeled with radioactive lipids. Blood samples were taken at fixed time intervals from the retro-orbital sinus, and clearance rates of the lipoproteins were assessed from the decline in plasma radioactivities. To follow the intracellular pathway of remnants in the liver, emulsions labeled with a fluorescent cholesteryl ester (BODIPY) were injected, and liver sections were processed and assayed by laser confocal microscopy. Catabolism of remnant cholesteryl esters was assessed by injecting emulsions labeled with cholesteryl[1-^14C]oleate and measuring the expired CO(2) from each animal.

In apoE-deficient mice, remnant removal from plasma was totally impeded, while the clearance of remnants in LDLr-deficient mice was similar to that in C57BL/6J control mice. The confocal micrographs of livers 20 min after injection of fluorescent chylomicron-like emulsions showed evenly distributed fluorescent particles in the hepatocytes from control mice. In contrast, the fluorescent particles were mainly located in sinusoidal spaces in LDLr-deficient mice. Three hours after injection the livers from control mice showed few fluorescent particles, indicating that remnants have been catabolized, while the sections from LDLr-deficient mice were still highly fluorescent. Micrographs from apoE-deficient mice showed no fluorescent particles in the liver at any time after injection. Measurement of expired radioactive CO(2) after injection of emulsions labeled in the fatty acid moiety of cholesteryl oleate indicated that remnant metabolism was slower in the LDLr-deficient mice and essentially nil in the apoE-deficient mice. Control mice had expired 50% of the injected label by 3 h after injection.

We conclude that under normal circumstances, chylomicron remnants are rapidly internalized by LDLr and catabolized in hepatocytes, with a critical requirement for apoE. When LDLr is absent, remnants are taken up by a second apoE-dependent pathway, first to the sinusoidal space of the liver, with subsequent slow endocytosis and slow catabolism. Hepatic clearance via this second pathway is increased by heparin, inhibited by lactoferrin, heparinase, and suramin, and down-regulated by feeding a high fat diet.


INTRODUCTION

Chylomicrons are responsible for transporting most dietary lipids from the intestinal tract into the bloodstream. Along with the bulk of lipids in the form of triacylglycerols (triglycerides) and phospholipids, a small proportion of the total mass of chylomicron is made up of cholesterol and cholesteryl esters. In the circulation, chylomicrons are metabolized by a two-stage process. Initially, the majority of the triglyceride is hydrolyzed by the action of lipoprotein lipase and taken up by extrahepatic tissues. The resulting smaller particles, known as chylomicron remnants, contain the residual triglyceride and all of the cholesterol and cholesteryl ester. The remnants have acquired apolipoprotein E (apoE) (^1)and are removed rapidly from the plasma by the liver into hepatocytes and delivered to lysosomes(1) . After hydrolysis of the cholesteryl esters by cholesterol ester hydrolase, the liberated fatty acids enter the pathways of oxidative metabolism and carbon dioxide is formed. The exhaled CO(2) can be quantified (2) to provide a measure for the internalization and catabolism of remnants.

The central role played by apoE in the metabolism of remnant lipoproteins has been well established by several lines of evidence. In type III hyperlipidemia, the presence of defective apoE, which does not bind to the liver receptors, leads to an accumulation of beta-very low density lipoproteins (beta-VLDL)(3) . For mice in which the apoE gene was targeted and nullified by homologous recombination (apoE knock-out), remnant lipoproteins accumulated in the plasma, and the mice developed hypercholesterolemia and premature atherosclerosis even on a chow (low fat) diet(4) . In contrast, transgenic mice overexpressing rat apoE (5) or human apoE-3 (6) showed enhanced remnant clearance and were protected from diet-induced hypercholesterolemia. Transgenic mice overexpressing human apoE-4 were less protected against hypercholesterolemia, and chylomicron clearance was enhanced when mice were fed a low fat diet but not when fed a high fat diet(7) . These findings have confirmed the critical role of apoE in directing the clearance of remnants from plasma and show that remnant clearance is modulated by the isoform of apoE as well as by the amount of apoE available.

Although the necessity of apoE for hepatic uptake of chylomicron remnants is well established, the putative hepatic receptor that mediates this uptake remains controversial. The frequently cited remnant (apoE) receptor (8) has not been identified. However, it is now well accepted that under normal circumstances the bulk of chylomicron remnants are cleared by the apoB/E receptor, also known as the low density lipoprotein receptor (LDLr)(9, 10) . Apart from LDLr, both the low density lipoprotein receptor-related protein (LRP) (11) and a newly defined lipolysis-stimulated receptor (12) have been proposed to serve as receptors mediating the removal of chylomicron remnants from the circulation. Recently, an important contributory role for heparan sulfate proteoglycans (HSPG) in remnant uptake has been clarified. The LDLr knockout mice provide a unique model for testing the contributions by receptors such as LRP or lipolysis-stimulated receptor and HSPG for remnant clearance in vivo.

Using the ^3H-retinol-fat tolerance test in apoE-deficient mice, Chang et al.(13) recently described an apoE-independent pathway for the hepatic clearance of chylomicron remnants. By 4-6 h after a fat meal containing ^3H-retinol, only 17-20% of the label remained in plasma, and up to 53% of the radioactivity was recovered in the liver. These findings are inconsistent with previous reports of hypercholesterolemia caused by the accumulation of triglyceride-rich lipoproteins (d < 1.006 g/ml) and the high incidence of atherosclerosis found in apoE-deficient mice (4, 14) and also fail to explain the high concentration of apoB-48 in apoE deficiency shown by Ishibashi et al.(9) .

In the present investigation, we measured plasma clearance and liver uptake of injected chylomicron-like emulsions in apoE-deficient mice and LDLr-deficient mice. Findings were compared with control C57BL/6J mice. Chylomicron-like emulsions mimic the metabolism of lymph chylomicrons (7, 15) and were preferred for this study to avoid injecting exogenous apolipoproteins that would complicate interpretation of results. To establish the intracellular pathway of the remnants, emulsions were labeled with a fluorescent cholesteryl ester (BODIPY). The emulsions were injected into the knockout and control mice, and the liver sections were processed for confocal microscopic images. We also traced the catabolism of the remnants by quantifying the exhaled CO(2) from both LDLr knockout and apoE knockout mice for comparison with controls, following injection of emulsions labeled with ^14C on the fatty acid moiety of cholesteryl oleate.


EXPERIMENTAL PROCEDURES

Materials

Egg yolk phosphatidylcholine was purchased from Lipid Products (Surrey, UK). Cholesterol, cholesteryl oleate, and triolein were from Nu-Chek-Prep. Radiochemicals, including [7-^3H]cholesterol, glycerol tri-[1-^14C]oleate, and cholesteryl [1-^14C]oleate, were purchased from Amersham Corp. As described earlier, ^3H-cholesteryl oleate was synthesized from [9,10-^3H]oleic acid (Amersham) and cholesterol(15) . The fluorescent probes, BODIPY and Texas Red dextran (lysine-fixable, with M(r) 70,000) were purchased from Molecular Probes Inc. Bovine lactoferrin and heparin were purchased from Sigma, and suramin was obtained from Bayer. Heparinase (EC 4.2.2.7, Sigma, Heparinase I, H 2519) was solubilized in 0.15 M NaCl. alpha(2)-Macroglobulin was purified from human plasma by zinc chelate chromatography according to the method of Porath et al.(16) and activated according to Vassiliou and Stanley (17) . The glutathione S-transferase and rat 39-kDa receptor-associated fusion protein (GST-RAP) was purified from a pGEX-GST-RAP construct generously supplied by Dr. K. Stanley and originally from Dr. J. Herz.

Animals

Colonies of apoE knockout mice and LDL receptor knockout mice were established from progenitor stocks obtained from the Jackson Laboratories (Bar Harbor, ME). The mice had been bred by sibling matings to obtain animals homozygous for the null mutation. C57BL/6J mice and Wistar male rats were obtained from the Animal Resources Centre (Murdoch, Australia). Male mice ranging in age from 9 to 12 weeks were used for this study. Animals were fed a pelleted diet containing approximately 5% fat unless otherwise specified.

Preparation of Chylomicrons

Male Wistar rats weighing approximately 250 g were fasted overnight and prepared surgically for the collection of intestinal lymph through a plastic tube implanted in the principal mesenteric lymph duct. After surgery, rats were placed in individual cages to recover from anesthesia and kept hydrated by a steady infusion of 0.154 M NaCl at 2.0 ml/h through a tube placed in the stomach at the time of lymph cannulation. Rats were then infused with Intralipid at a rate of 25 mg of triglyceride/h through the gastrostomy tube. An aliquot of 3 ml of phosphate-buffered saline (pH 7.4) containing 57 µmol of sodium taurocholate, 10 µCi of [1-^14C]palmitic acid, and 20 µCi of [7-^3H]cholesterol was infused via the same tube. Lymph was collected for 4 h into a vessel containing EDTA (1 mg/ml) and reduced glutathione (1.6 mM). Cells were removed from the lymph by centrifugation at 3,000 rpm for 10 min, solid KBr was added (0.14 g/ml) to raise the density to 1.1 g/ml, and the chylomicrons were isolated by density gradient centrifugation (18) .

Preparation of Chylomicron-like Lipid Emulsions

Chylomicron-like lipid emulsions labeled with cholesteryl [9,10-^3H]oleate and glycerol tri-[1-^14C]oleate, cholesteryl[1-^14C]oleate alone, or cholesteryl-BODIPY were prepared by sonicating a mixture of pure triolein, cholesteryl oleate, egg lecithin, and free cholesterol in 0.154 M NaCl, 10 mM HEPES (pH 7.4). Chylomicron-size particles of diameter 135-150 nm were purified from the sonicated mixture by serial ultracentrifugation in a density gradient. Details of the procedures and characterization of the emulsion particles have been given previously(15) .

Clearance

Anesthesia was induced in the mice by intraperitoneal injection of avertin (tribromoethanol). Exactly 50 µl of emulsion or lymph chylomicrons, containing approximately 250-300 µg of total lipid, was injected via a 30-gauge needle into a tail vein. The effects of other ligands on remnant clearance were tested by injecting a solution containing the effectors (lactoferrin, heparin, heparinase, RAP, alpha(2)-macroglobulin, or suramin) 1-5 min prior to emulsion injection. Three blood samples of approximately 75 µl were taken from a retro-orbital venous sinus of each animal at fixed time intervals following emulsion injection. Radioactivity in plasma was measured by liquid scintillation spectrometry. After collection of the final blood sample, the animal was exsanguinated, and the liver was excised for extraction of lipids and measurement of radioactivity.

Measurement of Remnant Metabolism from Carbon Dioxide in Expired Breath

Chylomicron-like emulsions labeled with cholesteryl[1-^14C]oleate were injected into a tail vein of conscious mice. Individual animals were then placed in a closed chamber through which a stream of room air was passed, and the air leaving the chamber was passed through solutions containing 0.21 mol/liter phenethylamine (Sigma), 50 ml of Permafluor (Packard, IL), 270 ml of methanol, and 410 ml of toluene, as described previously (19) . Aliquots of the solutions were then counted by liquid scintillation spectrometry to quantify expired carbon dioxide.

Diet Study

Groups of LDLr-deficient mice were fed for 3 weeks a high fat diet containing by weight, 15% fat (as dairy butter), 1% cholesterol, 0.5% sodium cholate, and 20% casein(7) . Control groups of LDLr-deficient mice were fed for 3 weeks a low fat diet of standard laboratory chow containing 5% fat.

Electrophoresis and Immunoblotting

The total plasma proteins (100 µg/lane) from mice fed the high fat and normal diet was applied to 5-25% gradient SDS-polyacrylamide gels for electrophoresis (15) and stained with Coomassie Blue.

Immunoblots were prepared by electrophoretically transferring proteins from other nonstained SDS-PAGE gels to nitrocellulose membranes. Individual membranes were incubated with a polyclonal antiserum to rat apoE and apoA-I (15) after blocking of the nonspecific binding sites with 10% albumin followed by 10% skim milk solution. The apoE and apoA-I bands were detected on these blots using HRP-conjugated secondary antibodies and the enhanced chemiluminescence (ECL) system (Amersham).

Biochemical Procedures

Protein concentrations were determined by the method of Lowry et al.(20) . Plasma cholesterol and triglyceride were determined enzymatically with assay kits from Randox Laboratories LTD (Antrim, United Kingdom).

Histology

Emulsions were double labeled with a fluorescent probe, cholesteryl-BODIPY, and a tracer amount of ^3H-cholesteryl ester. At 5 min, 20 min, or 3 h after tail vein injection of the emulsion, mice were anesthetized with avertin, and the abdomen was opened to expose the portal vein. Ice-cold saline or Texas Red dextran solution was perfused through the portal vein, and the liver was excised. Liver pieces (3-4 mm^3) were fixed in 4% paraformaldehyde in 0.1 M cacodylate buffer overnight, snap frozen with isopentane in liquid nitrogen, and sectioned on a cryostat (Bright, UK). Sections were collected on gelatin-coated slides, mounted in an aqueous medium, and examined by a confocal laser scanning microscope with 40 times lens, N.A., 1.0 (Bio-Rad MR-1000).

Statistics

Group means were compared by analysis of variance using the InStat program for Macintosh. Statistical significance was accepted with p < 0.05.


RESULTS

Plasma Clearance of Chylomicron-like Emulsions

Fig. 1A compares the plasma clearance of a chylomicron-like emulsion in the control, apoE-deficient, and LDLr-deficient mice. At 30 min after the injection, more than 85% of the injected emulsion was cleared from the plasma of the control and LDLr-deficient mice. In contrast, over 60% of the injected emulsion remained in the plasma of apoE-deficient mice. The differences in clearance were statistically significant (p < 0.05 at 10 min and p < 0.0001 at 20 and 30 min). The hepatic uptake of the emulsion is shown in Fig. 1B. Approximately 60% of the injected radioactivity was recovered in the liver of the control and LDLr-deficient mice, but only about 5% was recovered in the liver of the apoE-deficient mice. The removal of emulsion triglyceride in apoE-deficient mice was normal and comparable with triglyceride clearance in normal mice (results not shown). Triglyceride removal in LDLr-deficient mice was also not significantly different from that in control mice.


Figure 1: Plasma clearance and liver uptake of injected chylomicron-like emulsions in control C57BL/6J, LDLr-deficient, or apoE-deficient mice. A, emulsion lipids were labeled with ^3H-cholesteryl oleate to trace the clearance of the injected particles up to 30 min after injection. Results are means ± S.E. with n = 5 for apoE-deficient mice, 9 for control, and 14 for LDLr-deficient mice. Closed circle, control mice; open square, LDLr-deficient mice; open triangle, apoE-deficient mice. B, radioactivity recovered in the liver of control C57BL/6J, LDLr-deficient or apoE-deficient mice. Mice were anesthetized with avertin, and the animals were exsanguinated 30 min after the injection of radiolabeled emulsions. Hepatic uptake of the radiolabels was measured as described under ``Experimental Procedures.'' Results are means ± S.E. with n = 5 for apoE-deficient mice, 24 for control, and 26 for LDLr-deficient mice.



To confirm the results obtained with chylomicron-like emulsions, clearances of lymph chylomicrons were also measured. Plasma clearances of endogenously labeled rat lymph chylomicrons in control and LDLr-deficient mice were similar to those of chylomicron-like emulsions. Clearance of lymph chylomicrons in apoE-deficient mice was not measured, as the chylomicrons contained endogenous apoE from the donor rats.

Fluorescent Localization of Remnants in Liver Cells

Fig. 2A shows a series of confocal images of liver sections. As shown in the figures, 5 min after injection of the emulsion, fluorescent labeled remnants were associated with the liver cells in both the control and the LDLr-deficient mice but not with apoE-deficient mice. However, in the LDLr-deficient mice, remnants accumulated at the boundary of the sinusoidal spaces. By 20 min after injection, the fluorescent label remained evenly distributed in the hepatocytes of control mice, whereas in the LDLr-deficient mice, streaks of fluorescent remnants again accumulated in the sinusoidal spaces. Using Texas Red associated with dextran (M(r) 70,000) (a second fluorescent probe, which remained confined to the sinusoidal space), we confirmed that the accumulated remnant particles in the LDLr-deficient mice were localized to the sinusoidal spaces (Fig. 2B). At 3 h after the injection, little fluorescence was detected in the liver sections of the control mice, indicating that by this time remnants had been catabolized completely in the hepatocytes of control mice. In contrast, in LDLr-deficient mice, 3 h after injection of emulsion, fluorescence was now evenly distributed in the hepatocytes. No fluorescence was found in the hepatocytes of apoE-deficient mice at any time following injection of the fluorescence labeled emulsion.



Figure 2: Laser-scanning confocal micrographs of liver sections from mice. A, control C57BL/6J, LDLr-deficient, and apoE-deficient mice were injected with 50 µl of chylomicron-like emulsion labeled with cholesteryl-BODIPY and ^3H-cholesteryl oleate. At various time intervals mice were anesthetized, the liver was removed, and sections were processed for confocal microscopy as described under ``Experimental Procedures.'' B, LDLr-deficient mice were injected with the fluorescent emulsion and stained with Texas Red. At 20 min after emulsion injection, mice were anesthetized, and the liver was perfused through the portal vein with Texas Red in saline (1 mg/ml) for 1 min. The liver was removed and processed for confocal microscopy as described under ``Experimental Procedures.'' C, recovery of liver radioactivity in control C57BL/6J, LDLr-deficient, or apoE-deficient mice after the injection of the fluorescent radioactive labeled emulsions. Mice were anesthetized with avertin, and the animals were exsanguinated at 5 min, 20 min, or 3 h after the injection of emulsions. Hepatic uptake of the radiolabels was measured as described under ``Experimental Procedures.''



It was of interest to compare the hepatic uptake of the fluorescent label with the hepatic uptake of radioactivity after injection of the emulsion labeled with ^3H-cholesteryl oleate and the fluorescent cholesteryl ester. The hepatic recovery of ^3H-cholesteryl oleate after injection of the double labeled emulsion is shown in Fig. 2C. There is good agreement between the two labels at all time points. The amounts of radioactivity in the livers of control and LDLr-deficient mice were similar at 5 and 20 min after injection. After 3 h, little of the ^3H-cholesteryl oleate radioactivity, as with the fluorescent label, remained in the livers of control mice. Approximately 40% of the injected radioactivity remained in the livers of LDLr-deficient mice at 3 h. In contrast, the radioactivity recovered in the liver of apoE-deficient mice was less than 5% throughout the whole time course of the experiment. Therefore, the findings with the fluorescent study were confirmed by the radioactive label.

The catabolism of remnants by the liver was quantified by measuring the output of ^14CO(2) in the expired breath of the control, LDLr-deficient and apoE-deficient mice (19) . The rate of expiration of ^14CO(2) was much slower in the apoE-deficient mice than in the controls (p < 0.0001). The radioactivity in expired breath was also significantly less in the LDLr-deficient mice compared with controls (p < 0.0001), indicating a defect or delay in the catabolism of remnants removed from the plasma.

The Effect of Lactoferrin, Heparinase, Heparin, RAP, Suramin and alpha(2)-Macroglobulin on Remnant Clearance in Control and LDLr-deficient Mice

To elucidate the nature of the hepatic remnant uptake in the absence of LDLr, we compared the effects of lactoferrin (2 mg/mouse), heparin (5 units/mouse), heparinase (30 units/mouse), RAP-GST (1 mg/mouse), suramin (0.2 mg/mouse and 1 mg/mouse) and alpha(2)-macroglobulin (1 mg/mouse) on remnant clearance in control and LDLr-deficient mice.

In previous studies lactoferrin has been shown to delay clearance (21) and to inhibit the endocytosis of chylomicron remnants (22) in the rat. Fig. 3A shows that injection of both lactoferrin and heparinase prior to emulsion injection inhibited the clearance of chylomicron remnants similarly in control and LDLr-deficient mice. Heparinase appeared to be a more effective inhibitor of remnant removal than lactoferrin, with about 80% of the injected radioactivity remaining in plasma at 30 min (Fig. 3A). The removal of emulsion triglyceride closely mirrored that of cholesteryl oleate. Triglyceride clearance was fast in both control and LDLr-deficient mice but severely retarded in the presence of lactoferrin or heparinase. Heparinase also appeared to be more potent than lactoferrin in inhibiting triglyceride clearance (Fig. 3B). Consistent with the clearance data, the hepatic recovery of labeled emulsion cholesteryl oleate was reduced from about 60 to 12% (p < 0.0005) in both control and LDLr-deficient mice, in the presence of lactoferrin or heparinase (Fig. 3C). The hepatic recovery of labeled triglyceride was similar with and without the inhibitors.


Figure 3: Effects of lactoferrin and heparinase on plasma clearance and liver uptake of chylomicron-like lipid emulsions in control and LDLr-deficient mice. Emulsion lipids were labeled with ^3H-cholesteryl oleate (CO) and ^14C-triolein (TO) to trace the remnant clearance and triglyceride removal of the injected particles. An aliquot of lactoferrin (2 mg/mouse) and heparinase (30 units/mouse) was injected 1 and 5 min, respectively, before the injection of the emulsion. Closed circle, control mice; open square, LDLr-deficient mice; closed triangle, control mice with lactoferrin; open triangle, LDLr-deficient mice with lactoferrin; diamond, control with heparinase; cross, LDLr-deficient mice with heparinase. A, plasma clearance of emulsion ^3H-cholesteryl oleate; B, plasma clearance of ^14C-triolein; C, ^3H-cholesteryl oleate recovered in the liver of control C57BL/6J and LDLr-deficient mice.



In contrast to lactoferrin and heparinase, heparin increased the rates of lipolysis and remnant clearance of the injected emulsion in both control and LDLr-deficient mice (Fig. 4A). Heparin is known to release lipoprotein lipase from the vascular endothelial surface, and hence an increase in lipolysis is expected. As shown in Fig. 4A, 10 min after emulsion injection, the amount of radioactive cholesteryl oleate remaining in the plasma was about 10% in the presence of heparin, compared with 40% without heparin (p < 0.0005). Similarly, the amount of ^14C-labeled triolein remaining in plasma decreased from about 25 to about 5%, accompanied by a significant (p < 0.0005) increase in the liver uptake of ^14C-label (35% with heparin compared with 25% without) at 30 min after emulsion injection (Fig. 4D). Heparin also increased the uptake of cholesteryl oleate (Fig. 4C) in the liver of control and LDLr mice.


Figure 4: The effect of heparin on plasma clearance and liver uptake of chylomicron-like lipid emulsions in control and LDLr-deficient mice. Emulsion lipids were labeled with ^3H-cholesteryl oleate (CO) and ^14C-triolein (TO) to trace the remnant clearance and triglyceride removal of the injected particles. An aliquot of heparin (5 units/mouse) was injected 1 min before the injection of emulsions. Closed circle, control mice; open square, LDLr-deficient mice; diamond, control with heparin; cross, LDLr-deficient mice with heparin. A, plasma clearance of emulsion ^3H-cholesteryl oleate; B, plasma clearance of ^14C-triolein; C, ^3H-cholesteryl oleate recovered in the livers; D, ^14C-triolein recovered in the liver of control C57BL/6J and LDLr-deficient mice.



The clearance of chylomicron remnants in the presence of activated alpha(2)-macroglobulin was also compared in control and LDLr-deficient mice. Consistent with Choi and Cooper(23) , in control mice unlabeled activated alpha(2)-macroglobulin slightly inhibited (difference not significant) the plasma clearance of chylomicron remnants (results not shown). However, the slight inhibition was not observed in LDLr-deficient mice.

RAP, the 39-kDa protein that co-purifies with alpha(2)-macroglobulin, was injected as a fusion protein conjugated to GST. Because of the fast metabolism of RAP, the clearance of emulsion was measured at 5, 10, and 20 min. 1 mg/mouse of GST-RAP injected prior to emulsion injection did not affect the clearance of chylomicrons in control mice but slightly delayed the remnant clearance in LDLr-deficient mice at 10 min (p < 0.05) after emulsion injection (Fig. 5A). The removal of emulsion triglyceride in the presence of RAP was also delayed in the LDLr-deficient mice (Fig. 5B).


Figure 5: The effect of RAP on plasma clearance of chylomicron-like lipid emulsions in control and LDLr-deficient mice. Emulsion lipids were labeled with ^3H-cholesteryl oleate (CO) and ^14C-triolein (TO) to trace the remnant clearance and triglyceride removal of the injected particles. An aliquot of RAP-conjugated to GST (1 mg/mouse) was injected 1 min before the injection of emulsions. Closed circle, control mice; open square, LDLr-deficient mice; closed triangle, control mice with RAP; open triangle, LDLr-deficient mice with RAP. A, plasma clearance of emulsion ^3H-cholesteryl oleate; B, plasma clearance of ^14C-triolein.



Suramin, a polysulfated compound with a molecular weight of 1429, has been reported to be a potent inhibitor of remnant uptake in fibroblast cells(17) . In our experiments, a low dose of suramin (0.2 mg/mouse) did not affect remnant clearance in the control and LDLr-deficient mice. When the suramin dose was increased to 1 mg/mouse, clearance of emulsion triglyceride and remnants was almost completely abolished in the LDLr-deficient mice and to a lesser extent in control mice (Fig. 6, A and B). The inhibitory effect on emulsion clearance was more profound in the earlier time points, particularly at 5 and 10 min after the injection of emulsion, possibly due to the fast metabolism of suramin in vivo. The effects on emulsion remnant clearance of these competitors and inhibitors in the control and LDLr-deficient mice are summarized in Table 1.


Figure 6: The effect of suramin on plasma clearance of chylomicron-like lipid emulsions in control and LDLr-deficient mice. Emulsion lipids were labeled with ^3H-cholesteryl oleate (CO) and ^14C-triolein (TO) to trace the remnant clearance and triglyceride removal of the injected particles. An aliquot of suramin (1 mg/mouse) was injected 1 min before the injection of emulsions. Closed circle, control mice; open square, LDLr-deficient mice; closed triangle, control mice with suramin; open triangle, LDLr-deficient mice with suramin. A, plasma clearance of emulsion ^3H-cholesteryl oleate; B, plasma clearance of ^14C-triolein.





The Effect of a High Fat, High Cholesterol Atherogenic Diet on Clearance in LDLr-deficient Mice

We previously reported that plasma clearance of chylomicron remnants was retarded by a high fat, high cholesterol, atherogenic diet in control C57BL/6J and CD1 mice, while the lipolysis of emulsion triglyceride was accelerated(7) . In LDLr-deficient mice consuming a high fat diet for 3 weeks, the plasma clearance of the labeled emulsion cholesteryl ester was also greatly retarded (Fig. 7A). The removal of emulsion triglyceride in these high fat-fed mice was also faster than that in mice consuming chow, although the difference is not statistically significant (Fig. 7A). The liver uptake of emulsion cholesteryl oleate in the high fat-fed animals decreased to 21% (n = 4) of the injected dose, which is about one-third of the liver uptake in LDLr mice fed a normal diet (p < 0.0005, Fig. 7B).


Figure 7: The effect of a high fat diet on plasma clearance and liver uptake of chylomicron-like lipid emulsions in LDLr-deficient mice. Emulsion lipids were labeled with ^3H-cholesteryl oleate (CO) and ^14C-triolein (TO) to trace the remnant clearance and triglyceride removal of the injected particles. LDLr-deficient mice were fed for 3 weeks with a high fat diet prior to emulsion injection. A, plasma clearance of emulsion ^3H-cholesteryl oleate and ^14C-triolein. Closed square, cholesteryl oleate clearance in LDLr-deficient mice on chow; open square, LDLr-deficient mice on a high fat diet; closed triangle, triolein clearance in LDLr-deficient mice on chow; open triangle, triolein clearance in LDLr-deficient mice on a high fat diet. B, ^3H-cholesteryl oleate recovered in the liver of mice fed either chow or a high fat diet.



Table 2summarizes the plasma lipid profile in the LDLr-deficient mice fed the high fat diet. The total plasma cholesterol in these mice increased 5-fold to 1550 mg/dl, while the HDL cholesterol decreased from 112.5 mg/dl to 37.6 mg/dl. Plasma triglyceride in the high fat-fed animals increased 2.5-fold.



The plasma apolipoprotein profile in control, LDLr-deficient, and high fat-fed LDLr-deficient mice was compared by a gradient SDS-PAGE (Fig. 8). LDLr-deficient mice consuming chow (lanes 5-8) contained slightly more apoB-100 and apoE than control mice (lanes 9-11). No accumulation of apoB-48 was observed in the mice. In contrast, the LDLr-deficient mice consuming a high fat diet (lanes 1-4) accumulated high concentrations of apoE, apoB-48, and apoB-100 and contained less apoA1 than mice consuming chow. Immunoblots of similar gels with an polyclonal antibody to rat apoE and A1 confirmed the observations (results not shown).


Figure 8: SDS-PAGE of apolipoproteins from plasma in control C57BL/6 mice fed chow, LDLr-deficient mice fed chow, and LDLr-deficient mice fed a high fat diet. Lanes 1-4, LDLr-deficient mice fed high fat; lanes 5-8, LDLr-deficient mice fed chow, lanes 9-11, control mice fed chow.




DISCUSSION

In these experiments, we compared the clearance of chylomicron-like lipid emulsions in control C57BL/6J and mice lacking apoE or the LDL receptor (LDLr). The endocytosis and metabolism of remnants derived from the injected emulsions in these mice were visualized by confocal microscopy and quantified using the carbon dioxide breath test(19) . Lipid emulsions were preferred in these experiments because they do not contain any exogenous proteins or apolipoproteins, which may nullify the defects of the knockout mice. The emulsions become associated with the endogenous apoE of the recipient animals after intravenous injection and were metabolized similarly to lymph chylomicrons(24) .

Our results confirm the critical requirement for apoE in the hepatic clearance of chylomicron remnants. In mice deficient in apoE, more than 60% of the injected ^3H-cholesteryl oleate, which traces emulsion remnants, remained in plasma 30 min after injection, compared with 15% in the control or LDLr-deficient mice (Fig. 1A). Moreover, apoE-deficient mice had negligible hepatic recovery of the labeled cholesteryl oleate from the clearance study (Fig. 1B) and expired little radioactive carbon dioxide following injection of ^14C-cholesteryl oleate-labeled emulsion. The confocal images of liver sections following injection of fluorescent emulsions confirmed the delayed internalization of remnants into the hepatocytes. Our findings are contradictory to Chang et al. who recently reported the fast hepatic clearance of chylomicron remnants in apoE-deficient mice 4-6 h after a vitamin fat load labeled with ^3H-retinol (13) . In our experiments, chylomicron remnants were not cleared or metabolized in these mice for up to 3 h. The discrepancy is probably due to different methods used in the studies. Retinyl palmitate had been shown to clear differently from triglyceride lipoproteins(25) . Alternatively, the longer period of experimental time may have resulted in the lipoprotein particles being depleted of all core triglycerides and entering the liver via a totally different pathway independent of apoE, since we know that lipolysis is fast, and lipase activity is intact in these mice. Moreover, the efficient remnant clearance from plasma in the apoE-deficient mice shown by Chang et al. is inconsistent with earlier reports of hypercholesterolemia, atherogenesis(4, 14) , and increased plasma concentration of apoB-48 (9) .

The rates of chylomicron remnant clearance from plasma were similar in the control and LDLr-deficient mice, with similar liver uptakes. The expired radioactive carbon dioxide, however, was significantly lower in the LDLr-deficient mice than in the control animals, suggesting that in the absence of LDLr, catabolism of the chylomicron remnants is probably delayed or defective. The slow catabolism is probably due to the slow internalization of remnants via the LDLr-independent pathway. Results from the confocal microscopy agree with measurements of the expired ^14CO(2). In LDLr-deficient mice, remnants accumulated in sinusoidal spaces of the liver prior to internalization into the hepatocytes; these remnants also remained within the hepatocytes for a longer period (up to 3 or 4 h) in the LDLr-deficient mice. These findings are consistent with Herz et al.(26) who compared the endosomal uptake of radioactive labels to show a delay in the endocytosis of chylomicron remnants in LDLr-deficient mice.

The finding that lactoferrin inhibits remnant clearance in LDLr-deficient mice (Fig. 3A) is consistent with the inhibition of apoE-enriched beta-VLDL uptake by lactoferrin in human fibroblasts lacking LDLr(27) . Ji and Mahley (28) showed that lactoferrin bound to HSPG and to LRP in Chinese hamster ovary cells. Recently, Meilinger et al. found a stable lactoferrin-LRP complex in isolated endosome fractions(29) . In the LDLr-deficient mice, it is not known if the inhibition of remnant clearance is due to the binding of lactoferrin to cell surface HSPG or to LRP.

Similarly, injection of heparinase blocked hepatic clearance of remnants from plasma in both the control and the LDLr-deficient mice (Fig. 3A). Ji et al. recently showed that heparinase decreased the amount of liver HSPG and inhibited the hepatic clearance of chylomicrons, apoE-enriched chylomicron remnants, and apoE-enriched beta-VLDL (30) but not the clearance of LDL and alpha2-macroglobulin. This reinforces the importance of HSPG and apoE in hepatic chylomicron remnant clearance via the receptor pathway. Thus, results from the lactoferrin and heparinase studies suggest the involvement of HSPG, apoE, and receptors in the hepatic clearance of chylomicron remnants in both control and LDLr-deficient mice.

The mechanism for the slower removal of emulsion triglyceride in the presence of lactoferrin and heparinase is unclear (Fig. 3B). Triglyceride removal reflects the sum of two processes, i.e. lipolysis and remnant uptake by the liver. The slower clearance of triglyceride is partly attributable to the delay in the remnant clearance but is more likely to be due to slower lipolysis, as the rates of triglyceride removal in apoE-deficient mice, mice fed high fat diet(7) , and rats fed a high cholesterol diet (21) were all fast and normal. It is possible that the inhibitors also interact with the lipoprotein lipase, reducing the availability of lipases for the hydrolysis of triglycerides in the monolayer.

In contrast, injection of heparin increased the removal of both emulsion triglyceride and remnants (Fig. 4, A and B). The increase in remnant clearance in the presence of heparin is probably due to the faster remnant production; however, the increase in the rate of lipolysis is not enough to account for the increased remnant removal. Heparin has been known to increase the uptake of chylomicron remnants by isolated rat hepatocytes (31) and to increase remnant clearance in streptozotocin diabetic rats (32) and also in rats consuming a high cholesterol diet(21) , possibly by stabilizing hepatic lipase and increasing its secretion. Hepatic lipase has been reported to be involved in the binding of chylomicron remnants to receptors and the endocytosis of the remnants(33, 34) . The alternative explanation is that in the presence of heparin, binding sites in HSPG molecules originally occupied by the lipases are now available for the binding of remnants. The availability of HSPG has been reported to be directly related to the clearance of lipoprotein remnants. For example, in diabetes mellitus it has been reported that a decrease in concentration of HSPG led to poor chylomicron clearance and hypercholesterolemia(35) .

Consistent with the studies of Mokuno et al.(36) in the rat, we did not find any significant effect of alpha(2)-macroglobulin in plasma clearance or the hepatic uptake of chylomicron remnants. In contrast, while RAP did not affect the remnant clearance from plasma in control mice, it delayed (p < 0.05) the remnant and triglyceride clearance in LDLr-deficient mice, suggesting the involvement of LRP. RAP has been known to block the binding of ligands to LRP but only interacts weakly with LDLr(36) . In the presence of LDLr, RAP did not inhibit remnant uptake, as shown by Willnow et al.(37). Herz et al.(38) reported that in FH fibroblasts lacking LDLr, RAP inhibited up to 80% of cholesterol esterification stimulated by the apoE-enriched beta-VLDL, but RAP had no effect on cholesteryl ester formation in normal fibroblasts. The effect of RAP on remnant clearance is relatively less marked in vivo, probably because of its short half-life when compared with remnants. When the concentration of RAP was sustained by gene transfer using an adenoviral vector to the liver of LDLr-deficient mice, hepatic remnant uptake was effectively inhibited(39) . Mokuno et al.(36) also demonstrated that GST-RAP produced a weak inhibitory effect on the hepatic uptake of apoE-enriched chylomicrons.

Suramin is a highly sulfated compound, structurally unrelated to heparin or dextran sulfate. The inhibition of lipoprotein uptake has been ascribed to its polyanionic nature. Due to its toxicity, suramin was initially tested at a low dose (0.2 mg in each animal) without producing effects on clearance or hepatic uptake. When the dose was increased to 1 mg/animal, suramin effectively inhibited the clearance of both triglyceride and remnants (Fig. 6, A and B) in LDLr mice and, to a lesser extent, in control mice. The mechanism by which suramin inhibits remnant clearance is still unclear but could probably be attributable to its binding to the lipases, the ligands, or the receptors, although the more profound inhibitory effect produced in LDLr-deficient mice cannot be determined without further studies.

A high fat, high cholesterol, atherogenic diet is known to retard chylomicron remnant clearance in normal and apoE-4 transgenic mice, while the removal of emulsion triglyceride was increased due to an increase in lipase concentration(7) . In LDLr-deficient mice consuming a high fat diet, plasma clearance and liver uptake of remnants are greatly retarded (Fig. 7). Lipolysis of emulsion triglyceride increased, but not to the extent observed for the normal and transgenic mice expressing apoE-4(7) . The high fat diet elevated the plasma levels of apoB-48, apoB-100, and apoE, consistent with Ishibashi et al.(9) . In addition, a lower HDL-cholesterol and apoA-I concentration was also observed in the LDLr mice after high fat feeding.

In conclusion, LDLr and apoE are both required for the normal fast internalization and metabolism of chylomicron remnants by the liver. An alternative apoE-dependent pathway operates to internalize chylomicron remnants in the absence of LDLr. The catabolism of remnants via this pathway is significantly slower when compared with the LDLr endocytotic pathway, probably due to the slow internalization of remnants. From the competition studies with lactoferrin, heparinase, heparin, and RAP, it appears that both HSPG and LRP are required in this pathway. Whether or not LRP is involved synergistic by or independent to the HSPG needs further investigation.


FOOTNOTES

*
This work was supported by the Arnold Yeldham and Mary Raine Medical Research Foundation of the University of Western Australia and the National Health & Medical Research Council of Australia. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed: Dept. of Physiology, University of Western Australia, Nedlands 6907, Australia. Fax: 61-9-380-1025; mortimer@uniwa.edu.uwa.au.

(^1)
The abbreviations used are: apoE, apolipoprotein E; LDLr, low density lipoprotein receptor; VLDL, very low density lipoprotein(s); LRP, low density lipoprotein receptor related protein; GST, glutathione S-transferase; RAP, receptor-associated protein; HSPG(s), heparan sulfate proteoglycans.


ACKNOWLEDGEMENTS

We thank A. Light and Dr. U. Seydel of the Centre for Cellular and Molecular Biology, for technical assistance with the confocal microscopy.


REFERENCES

  1. Redgrave, T. G. (1983) Int. Rev. Physiol. 28, 103-130 [Medline] [Order article via Infotrieve]
  2. Godfrey, P., and Snyder, F. (1962) Anal. Biochem. 4, 310-315 [Medline] [Order article via Infotrieve]
  3. Mahley, R. W. (1988) Science 240, 622-630 [Medline] [Order article via Infotrieve]
  4. Zhang, S. H., Reddick, R. L., Piedrahita, J. A., and Maeda, N. (1992) Science 258, 468-471 [Medline] [Order article via Infotrieve]
  5. Shimano, H., Yamada, N., Katsuki, M., Shimada, M., Gotoda, T., Harada, K., Murase, T., Fukazawa, C., Takaku, F., and Yazaki, Y. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 1750-1754 [Abstract]
  6. Desilva, H. V., Lauer, S. J., Mahley, R. W., Weisgraber, K. H., and Taylor, J. M. (1993) Biochem. Soc. Trans. 21, 483-487 [Medline] [Order article via Infotrieve]
  7. Mortimer, B. C., Redgrave, T. G., Spangler, E. A., Verstuyft, J. G., and Rubin, E. M. (1994) Arterioscler. Thromb. 14, 1542-1552 [Abstract]
  8. Kita, T., Goldstein, J. L., Brown, M. S., Watanabe, Y., Hornick, C. A., and Havel, R. J. (1982) Proc. Natl. Acad. Sci. U. S. A. 79, 3623-3627 [Abstract]
  9. Ishibashi, S., Herz, J., Maeda, N., Goldstein, J. L., and Brown, M. S. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 4431-4435 [Abstract]
  10. Mahley, R. W., Ji, Z-S., Brecht, W. J., Miranda, R. D., and He, D-P. (1994) Ann. N.Y. Acad. Sci. 737, 39-52 [Medline] [Order article via Infotrieve]
  11. Herz, J., Hamann, U., Rogne, S., Myklebost, O., Gausepohl, H., and Stanley, K. K. (1988) EMBO J. 7, 4119-4127 [Abstract]
  12. Yen, F. T., Mann, C. J., Guermani, L. M., Hannouche, N. F., Hubert, N., Hornick, C. A., Bordeau, V. N., Agnani, G., and Bihain, B. E. (1994) Biochemistry 33, 1172-1180 [Medline] [Order article via Infotrieve]
  13. Chang, S., Zhang, S. H., Maeda, N., and Borensztajn, J. (1994) Biochim. Biophys. Acta 1215, 205-208 [Medline] [Order article via Infotrieve]
  14. Plump, A. S., Smith, J. D., Hayek, T., Aalto-etälä, S. K., Walsh, A., Verstuyft, J. G., Rubin, E. M., and Breslow, J. L. (1992) Cell 71, 343-353 [Medline] [Order article via Infotrieve]
  15. Mortimer, B. C., Simmonds, W. J., Cockman, S. J., Stick, R. V., and Redgrave, T. G. (1990) Biochim. Biophys. Acta 1046, 46-56 [Medline] [Order article via Infotrieve]
  16. Porath, J., Carlsson, J., Olsson, I., and Belfrage, G. (1975) Nature 258, 598-599 [Medline] [Order article via Infotrieve]
  17. Vassiliou, G., and Stanley, K. K. (1994) J. Biol. Chem. 269, 15172-15178 [Abstract/Free Full Text]
  18. Redgrave, T. G., Roberts, D. C. K., and West, C. E. (1975) Anal. Biochem. 65, 42-49 [Medline] [Order article via Infotrieve]
  19. Redgrave, T. G., Martins, I. J., and Mortimer, B-C. (1995) J. Lipid Res. , in press
  20. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951) J. Biol. Chem. 193, 265-275 [Free Full Text]
  21. Callow, M. J., Mortimer, B-C., and Redgrave, T. G. (1993) Biochem. Mol. Biol. Int. 29, 913-919 [Medline] [Order article via Infotrieve]
  22. Huettinger, M., Retzek, H., Hermann, M., and Goldenberg, H. (1992) J. Biol. Chem. 267, 18551-18557 [Abstract/Free Full Text]
  23. Choi, S. Y., and Cooper, A. D. (1993) J. Biol. Chem. 268, 15804-15811 [Abstract/Free Full Text]
  24. Redgrave, T. G., and Maranhao, R. C. (1985) Biochim. Biophys. Acta 835, 104-112 [Medline] [Order article via Infotrieve]
  25. Krasinski, S. D., Cohn, J. S., Russell, R. M., and Schaefer, E. J. (1990) Metabolism 39, 357-365 [Medline] [Order article via Infotrieve]
  26. Herz, J., Qiu, S-Q., Oesterie, A., Desilva, H. V., Shafi, S., and Havel, J. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 4611-4615 [Abstract]
  27. Willnow, T. E., Goldstein, J. L., Orth, K., Brown, M. S., and Herz, J. (1992) J. Biol. Chem. 267, 26172-26180 [Abstract/Free Full Text]
  28. Ji, Z. S., and Mahley, R. W. (1994) Arterioscler. Thromb. 14, 2025-2031 [Abstract]
  29. Meilinger, M., Haumer, M., Szakmary, K. A., Steinbock, F., Scheiber, B., Goldenberg, H., and Huettinger, M. (1995) FEBS Lett. 360, 70-74 [CrossRef][Medline] [Order article via Infotrieve]
  30. Ji, Z. S., Sanan, D. A., and Mahley, R. W. (1995) J. Lipid Res. 36, 583-592 [Abstract]
  31. Sultan, F., Lagrange, D., Le Liepvre, X., and Griglio, S. (1989) Biochem. J. 258, 587-594 [Medline] [Order article via Infotrieve]
  32. Redgrave, T. G., and Callow, M. J. (1990) Metabolism 39, 1-10 [Medline] [Order article via Infotrieve]
  33. Shafi, S., Brady, S. E., Bensadoun, A., and Havel, R. J. (1994) J. Lipid Res. 35, 709-720 [Abstract]
  34. Diard, P., Malewiak, M. I., Lagrange, D., and Griglio, S. (1994) Biochem. J. 299, 889-894 [Medline] [Order article via Infotrieve]
  35. Colette, C., Etienne, P., Percheron, C., Bancel, E., Boniface, H., Lapinski, H., and Monnier, L. (1994) Diabetes Nutr. Metab. 7, 295-303
  36. Mokuno, H., Brady, S., Kottie, L., Herz, J., and Havel, R. J. (1994) J. Biol. Chem. 69, 13238-13243
  37. Willnow, T. E., Armstrong, S. A., Hammer, R. E., and Herz, J. (1995) Proc. Natl. Acad. Sci. U. S. A. 4537-4541
  38. Herz, J., Goldstein, J. L., Strickland, D. K., Ho, Y. K., and Brown, M. S. (1991) J. Biol. Chem. 266, 21232-21238 [Abstract/Free Full Text]
  39. Willnow, T. E., Sheng, Z. Q., Ishibashi, S., and Herz, J. (1994) Science 264, 1471-1474 [Medline] [Order article via Infotrieve]

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.